Light Therapy + Occupational Therapy for Genitourinary Cancers
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: City of Hope Medical Center
Disqualifiers: Severe sleep disorders, Eye diseases, Severe psychological impairment, others
No Placebo Group
Approved in 4 Jurisdictions
Trial Summary
What is the purpose of this trial?
This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence-based intervention for managing fatigue in cancer patients. The use of light therapy can provide a low burden, inexpensive, and easy to disseminate intervention approach that can potentially have a larger impact on CRF. In addition, occupational therapy is a standard, but often underutilized, component of the multi-disciplinary approach to cancer care. Using the combination of light therapy and occupational therapy may be effective in CRF management.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves light and occupational therapy, it seems likely that you can continue your existing treatments, especially since participants must be on active cancer treatment.
What data supports the effectiveness of the treatment Light Therapy + Occupational Therapy for Genitourinary Cancers?
How does the treatment of light therapy combined with occupational therapy for genitourinary cancers differ from other treatments?
This treatment is unique because it combines light therapy, which uses specific wavelengths of light to potentially improve mood and energy, with occupational therapy, which helps patients regain skills and improve their quality of life. Unlike standard drug treatments like androgen deprivation therapy (ADT) for prostate cancer, which can have significant side effects, this approach focuses on enhancing overall well-being and daily functioning.678910
Eligibility Criteria
This trial is for adults over 18 with genitourinary cancers like prostate, kidney, and bladder cancer who are experiencing mild to moderate fatigue during treatment. They must speak English well enough to consent and have a life expectancy of at least six months. People with severe sleep disorders, psychological impairments, recent eye surgery or diseases affecting light processing in the eyes, sensitivity to light or seizures cannot participate.Inclusion Criteria
Sufficiently fluent in English
I am willing and able to agree to participate on my own.
I am currently undergoing treatment such as chemotherapy, immunotherapy, or radiotherapy.
See 4 more
Exclusion Criteria
Severe psychological impairment (e.g., bipolar disorder or manic episodes)
I have a severe sleep disorder like narcolepsy.
I have used light therapy for fatigue or depression.
See 7 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive light therapy and/or occupational therapy interventions for 3 months
3 months
6 follow-up sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment
3 months
Treatment Details
Interventions
- Bright White Light Therapy (Procedure)
- Occupational Therapy (Behavioral Intervention)
Trial OverviewThe study is testing whether combining bright white light therapy with occupational therapy can help reduce fatigue in patients undergoing treatment for genitourinary cancers. Light therapy is simple and low-cost while occupational therapy helps manage daily activities; together they might improve energy levels.
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Group I: Arm III (OT, BWL)Experimental Treatment3 Interventions
Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses and to complete the occupational therapist-led session over 60 minutes.
Group II: Arm II (OT)Experimental Treatment2 Interventions
Patients undergo 6 occupational therapist-led sessions over 60 minutes each.
Group III: Arm I (BWL)Experimental Treatment2 Interventions
Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses.
Group IV: Arm IV (Control)Active Control2 Interventions
Patients undergo routine treatment and usual follow up care with their medical oncologist.
Occupational Therapy is already approved in United States, European Union, Canada, Australia for the following indications:
🇺🇸 Approved in United States as Occupational Therapy for:
- Rehabilitation
- Physical disabilities
- Mental health conditions
- Cancer-related fatigue
🇪🇺 Approved in European Union as Occupational Therapy for:
- Rehabilitation
- Physical disabilities
- Mental health conditions
- Cancer-related fatigue
🇨🇦 Approved in Canada as Occupational Therapy for:
- Rehabilitation
- Physical disabilities
- Mental health conditions
- Cancer-related fatigue
🇦🇺 Approved in Australia as Occupational Therapy for:
- Rehabilitation
- Physical disabilities
- Mental health conditions
- Cancer-related fatigue
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
City of Hope Medical CenterDuarte, CA
Loading ...
Who Is Running the Clinical Trial?
City of Hope Medical CenterLead Sponsor
National Cancer Institute (NCI)Collaborator
References
Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. [2021]The impact of occupational therapy (OT) and physical therapy (PT) on functional outcomes in older adults with cancer is unknown.
Reasons for and outcome of occupational therapy consultation and treatment in the context of multidisciplinary cancer rehabilitation; a historical cohort study. [2021]The aim of this study was to investigate reasons why people consulted an occupational therapist following cancer treatment, and to examine the outcome of occupational therapy interventions, in the context of multidisciplinary rehabilitation.
Effects of occupational therapy on quality of life of patients with metastatic prostate cancer. A randomized controlled study. [2023]To evaluate the efficiency of occupational therapy relative to a home program in improving quality of life (QoL) among men who were treated for metastatic prostate cancer (MPC).
Occupational therapy intervention for cancer patients following hospital discharge: How and when should we intervene? A systematic review. [2021]Advances in cancer treatment over the last decade have led to increased survival rates. As a result, survivors are living longer with and beyond cancer, often with greater levels of morbidity. Occupational therapists, with their focus on remedial and compensatory strategies to improve function and participation, are well suited to assess and intervene with this population. Despite this, little research exists to demonstrate the efficacy of interventions and value of the occupational therapy role. This systematic review aimed to review how and when occupational therapists provide services for adult patients with cancer and identify where they add the most value.
Occupational Therapy for Adults With Cancer: Why It Matters. [2022]Adults with cancer may be at risk for limitations in functional status and quality of life (QOL). Occupational therapy is a supportive service with the specific mission to help people functionally engage in life as safely and independently as possible with the primary goal of improving QOL. Unfortunately, for people with cancer, occupational therapy remains underused. The overall purpose of this review is to provide an understanding of what occupational therapy is and its relevance to patients with cancer, highlight the reasons to refer, and, last, provide general advice on how to access services.
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. [2006]We review the effectiveness of androgen-deprivation therapy (ADT) in the management of prostate cancer, and the effect that this treatment has on a patient's quality of life (QoL), based on discussions held at a European symposium on the management of prostate cancer. The overall QoL is reduced in asymptomatic men, and there are known decreases in cognitive function, self-esteem, libido and sexual function. Hot flashes are also a frequent problem. Prolonged ADT can lead to osteoporosis and subsequently fractures. Various effective methods exist to manage and minimize these side-effects; some are specific to the side-effect, whereas other more general methods include lifestyle changes, specific drugs and added hormonal manipulations. Intermittent ADT for patients taking luteinizing hormone-releasing hormone agonists offers a promising method to reduce adverse effects, and possibly increases the time to androgen independence. Initial studies indicate that prostate-specific antigen-based progression with intermittent ADT is similar to that seen with continuous ADT, but there is a reduction in side-effects, leading to an improvement in QoL.
Depression and androgen deprivation therapy for prostate cancer: a prospective controlled study. [2018]The main goal of this controlled study was to compare the presence of depressive symptoms and disorders in men receiving a combination of androgen deprivation therapy and radiation therapy (ADT-RTH) to men receiving RTH only.
Lower urinary tract symptoms in patients with advanced prostate cancer: What are the outcomes of androgen deprivation therapy? [2022]Androgen deprivation therapy (ADT) is accepted as the first-line treatment of advanced prostate cancer. This study sets out to determine the outcomes of ADT in reducing lower urinary tract symptoms (LUTS) in patients with advanced prostate cancer and also to determine the quality of life (QoL) of the patients.
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. [2021]Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of more potent but shorter-term androgen inhibition in men with intermediate- or high-risk localized PC would synergize with definitive RT to provide short-term testosterone recovery and improve disease control.
Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. [2018]Radiotherapy (RT) in combination with androgen deprivation therapy (ADT) for prostate cancer (PCa) carries a risk of gastrointestinal (GI) and genitourinary toxicity, which might affect the quality of life (QoL). The purpose of this study was to assess the QoL in patients with PCa before, during and after radiotherapy (RT) and to compare the QoL 1 year after RT to a normal population.